BONDURANT STUART 4
4 · PHARMACEUTICAL PRODUCT DEVELOPMENT INC · Filed Dec 6, 2011
Insider Transaction Report
Form 4
BONDURANT STUART
Director
Transactions
- Disposition to Issuer
Stock Options (to buy)
2011-12-05−6,341→ 0 totalExercise: $32.67→ Common Stock (6,341 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−5,650→ 0 totalExercise: $22.98→ Common Stock (5,650 underlying) - Disposition to Issuer
Common Stock
2011-12-05$33.25/sh−21,479$714,177→ 0 total - Disposition to Issuer
Stock Options (to buy)
2011-12-05−6,485→ 0 totalExercise: $41.32→ Common Stock (6,485 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−9,095→ 0 totalExercise: $28.52→ Common Stock (9,095 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−10,496→ 0 totalExercise: $24.52→ Common Stock (10,496 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−14,053→ 0 totalExercise: $19.19→ Common Stock (14,053 underlying) - Disposition to Issuer
Stock Options (to buy)
2011-12-05−4,113→ 0 totalExercise: $34.18→ Common Stock (4,113 underlying)
Footnotes (2)
- [F1]Pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Prodcut Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger"), each of these shares of common stock was automatically converted into the right to receive $33.25.
- [F2]These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference, if any, between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes.